Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Cimerli. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Ranibizumab-Eqrn (sold as Cimerli), first approved Aug 2, 2022, with 0 new uses approved and 0 published complete response letters.
First approved: Aug 2, 2022
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $30.2M
First approved in the EU: Jan 22, 2007
First approved in Japan: Jan 21, 2009
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Cimerli
Part B
$30.2M
-86%
19,257
Cimerli
Part D
$18K
-92%
0
Approvals in the EU (EMA)
First approved in the EU 186 months before the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 162 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
LucentisA drug with a new additional indication and a new dosage for the treatment of retinopathy of prematurity. · Novartis Pharma K.K. · Nov 22, 2019
Lucentis solutionA drug with a new additional indication for the treatment of diabetic macular edema. · Novartis Pharma K.K. · Feb 21, 2014
LucentisA drug with new additional indications and a new dosage for the treatment of macular edema following retinal vein occlusion and choroidal neovascularisasion… · Novartis Pharma K.K. · Aug 20, 2013
Lucentis, new ingredientA drug containing a new active ingredient indicated for treatment of age-related macular degeneration with concurrent choroidal neovascularization. · Novartis Pharma K.K. · Jan 21, 2009
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
